CME Grant Disclosures for 2012 to 3rd Quarter of 2013

0 591

We have compiled a chart of companies that have disclosed their educational grant payments for 2012-2013. Some companies have disclosure information for several years. Now that grants are subject to Sunshine Act reporting requirements for teaching hospitals, it is likely more companies will begin to post such payments to teaching hospitals. We will add additional information as it becomes available.

Company 2013 2012 2011 2010 2009
Abbott Q1 Q1 Q1 Q1
Q2 Q2 Q2 Q2
Q3 Q3 Q3 Q3
Q4 Q4 Q4
Allergan Q1 & Q2 Q1 & Q2 Q1 & Q2
Q3 & Q4 Q3 & Q4 Q3
Amgen Q1 Q1 Q1 Q1 Q1
Q2 Q2 Q2 Q2 Q2
Q3 Q3 Q3 Q3 Q3
Q4 Q4 Q4 Q4
Astellas Pharma US, Inc. Q1 Q1 Q1
Q2 Q2 Q2 Q2
Q3 Q3 Q3 Q3
Q4 Q4 Q4 Q4
Astra Zeneca Q1 & Q2 Q1& Q2 Q1 & Q2 Q1 & Q2 Q1 & Q2
Q3 & Q4 Q3 &Q4 Q3 &Q4 Q3 &Q4
Bristol-Myers Squibb Q1 Q1
Q2 Q2
Q3 Q3
Q4
Forest Labs Q1 2012 Full Year 2011 Full Year 2010 Full Year
Q2
Q3
Genentech 2012 Full Year 2011 Full Year 2010 Full Year
Biosense Webster Q1 & Q2 Q3 & Q4 (starting page 3)
Janssen Biotech Q1-Q3  
Cordis Q1 & Q2 Q3 & Q4 (starting page 3)
Depuy Mitek, Inc. Q1 & Q2 Q3 & Q4 (starting page 3)
Depuy Orthopaedics, Inc. Q1 & Q2 Q3 & Q4 (starting page 3)
Depuy Spine, Inc. Q1 & Q2 Q3 & Q4 (starting page 3)
Codman and Shurtleff, Inc. Q1 & Q2 Q3 & Q4 (starting page 3)
Ethicon Q1 & Q2 Q3 & Q4 (starting page 3)
Janssen Pharmaceuticals, Inc. Q1-Q3
Janessen Biotech, Inc. Q1-Q3 Q1 2011
Janssen Therapeutics Q1-Q3
Therakos 2012:
Q1 & Q2
2011:
Q3 & Q4 (starts page 3)
Eli Lilly Q1-Q3 2012 Full Year 2011 Full Year 2010 Full Year
Merck 2013 Full Year (all reports available mid-page) 2012 Full Year 2011 Full Year 2010 Full Year 2009 Full Year
Pfizer Q1 2012 Full Year 2011 Full Year 2010 Full Year 2009 Full Year
Q2
Q3
Sanofi Aventis Q1 Q1 Q1 Q1
Q2 Q2 Q2 Q2
Q3 Q3 Q3
Q4 Q4 Q4
Shire Q1 Q1 Q1 Q1 Q1
Q2 Q2 Q2 Q2 Q2
Q3 Q3 Q3 Q3 Q3
Q4 Q4 Q4 Q4

 

Leave A Reply

Your email address will not be published.